Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1934-1939

  Stevens, K N ^a   Garcia Closas, M ^b   Fredericksen, Z ^a   Kosel, M ^a   Pankratz, V S ^a   Hopper, J L ^c   Dite, G S ^c   Apicella, C ^c   Southey, M C ^c   Schmidt, M K ^d   Broeks, A ^d   Van T Veer, L J ^d   Tollenaar, R A E M ^e   Fasching, P A ^f,g   Beckmann, M W ^g   Hein, A ^g   Ekici, A B ^h   Johnson, N ^b   Peto, J ⁱ   Dos Santos Silva, I ⁱ   Gibson, L ⁱ   Sawyer, E ^j   Tomlinson, I ^k   Kerin, M J ^l   Chanock, S ^m   Lissowska, J ⁿ   Hunter, D J ^o   Hoover, R N ^m   Thomas, G D ^m   Milne, R L ^p   Pérez, Ji Arias ^q   Gonzalez Neira A ^p   Benitez J ^p   Burwinkel, B ^r,s   Meindl, A ^t   Schmutzler, R K ^u   Bartrar, C R ^v   Hamann, U ^s   Ko, Y D ^w   Bruning T ^x   Chang Claude, J ^s   Hein, R ^s   Wang Gohrke, S ^y   Dork T ^z   Schurmann P ^z   Bremer, M ^z   Hillemanns, P ^z   Bogdanova, N ^z   Zalutsky, J V ^z   Rogov, Y I ^z   Antonenkova, N ^z   Lindblom, A ^aa   Margolin, S ^aa   Mannermaa, A ^ab   Kataja, V ^ac   Kosma, V M ^ab   Hartikainen, J ^ab   Chenevix Trench, G ^ad   Chen, X ^ad   Peterlongo, P ^ae   Bonanni, B ^af   Bernard, L ^af   Manoukian, S ^ae   Wang, X ^a   Cerhan, J ^a   Vachon, C M ^a   Olson, J ^a   Giles, G G ^c,ag   Baglietto, L ^c,ag   McLean, C A ^ah   Severi, G ^c,ag   John, E M ^ai   Miron, A ^aj   Winqvist, R ^ak   Pylkas K ^aq   Jukkola Vuorinen, A ^ak   Grip, M ^ak   Andrulis, I ^al,am,an   Knight, J A ^am,ao   Glendon, G ^al   Mulligan, A M ^an,ap   Cox, A ^aq   Brock, I W ^aq   Elliott, G ^ar   Cross, S S ^aq   Pharoah, P P ^as   Dunning, A M ^as   Pooley, K A ^as   Humphreys, M K ^as   Wang, J ^as   Kang, D ^at   Yoo, K Y ^at   Noh, D Y ^at   Sangrajrang, S ^au   Gabrieau, V ^av   Brennan, P ^av   McKay, J ^av   Anton Culver, H ^aw   Ziogas, A ^aw   Couch, F J ^a   Easton, D F ^as   more..

^a MAYO CLINIC   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Friedrich Alexander University Erlangen Nuremberg   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j GUY S HOSPITAL   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY HOSPITAL GALWAY   (Ireland)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^p Centro Nacional de Investigaciones Oncológicas   (Spain)

^q HOSPITAL MONTE NARANCO   (Spain)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^v UNIVERSITY OF HEIDELBERG   (Germany)

^w Johanniter Krankenhaus   (Germany)

^x INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^y UNIVERSITY OF ULM   (Germany)

^z HANNOVER MEDICAL SCHOOL   (Germany)

^aa KAROLINSKA INSTITUTE   (Sweden)

^ab UNIVERSITY OF EASTERN FINLAND   (Finland)

^ac KUOPIO UNIVERSITY HOSPITAL   (Finland)

^ad QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^ae NATIONAL CANCER INSTITUTE   (Italy)

^af EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ag CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ah ALFRED HOSPITAL   (Australia)

^ai CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^aj DANA FARBER CANCER INSTITUTE   (United States)

^ak UNIVERSITY OF OULU   (Finland)

^al CANCER CARE ONTARIO   (Canada)

^am MOUNT SINAI HOSPITAL   (Canada)

^an UNIVERSITY OF TORONTO   (Canada)

^ao UNIVERSITY OF TORONTO   (Canada)

^ap ST MICHAEL'S HOSPITAL   (Canada)

^aq UNIVERSITY OF SHEFFIELD   (United Kingdom)

^ar UNIVERSITY OF MANCHESTER   (United Kingdom)

^as UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^at Seoul National University College of Medicine   (South Korea)

^au NATIONAL CANCER INSTITUTE   (Thailand)

^av INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^aw UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Association study; Genetic susceptibility; Neoplasms

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; UNCLASSIFIED DRUG; PIK3CA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; EUROPEAN AMERICAN; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84856024444     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.448     Document Type: Article

References (23)

1. Aleskandarany MA Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122(1): 45-53
2. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8): 772-775 (Pubitemid 41351083)
3. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21): 7678-7681 (Pubitemid 39446895)
4. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573): 1655-1657 (Pubitemid 34579158)
5. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2): 193-204
6. Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu Rev Biochem 67: 481-507 (Pubitemid 28411136)
7. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengstrom M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4(4): e1000054
8. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16): 5049-5059
9. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94(4): 455-459 (Pubitemid 43289745)
10. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15(4): 1064-1069
11. Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96(1): 91-95
12. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8(9): 1352-1358
13. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptorpositive breast cancer. Proc Natl Acad Sci USA 107(22): 10208-10213
14. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY (2000) PIK3CA as an oncogene in cervical cancer. Oncogene 19(23): 2739-2744 (Pubitemid 30339223)
15. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13(12): 3577-3584 (Pubitemid 46955118)
16. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7): 2554-2559 (Pubitemid 40490050)
17. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18(1): 77-82 (Pubitemid 43740454)
18. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670): 554 (Pubitemid 38541907)
19. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21(1): 99-102 (Pubitemid 29036292)
20. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15): 6084-6091
21. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni Jr JF, Hoover RN, Chanock SJ, Hunter DJ (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5): 579-584
22. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W, Rider DN, Vachon CM, Cerhan JR, Olson JE, Couch FJ (2008) Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 17(8): 2101-2108
23. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3): 250-263